MIRM catalyst calendar

Mirum Pharmaceuticals, Inc.

Upcoming catalysts
9
Cash runway
5.7 months
Cash & investments
$438M
Phase 3 programs
8

Mirum Pharmaceuticals, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) on October 15, 2026. There are 9 upcoming events on record.

Cash runway is approximately 5.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 26 concluded trials, 85% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) Trial Milestone Phase 3
December 23, 2026 est. Next quarterly earnings (projected) Earnings —
January 15, 2027 A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis Trial Milestone Phase 2
June 30, 2027 A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) Trial Milestone Phase 3
August 31, 2027 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Trial Milestone Phase 2/Phase 3
October 15, 2027 Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) Trial Milestone Phase 2
January 12, 2029 MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP) Trial Milestone Phase 2
May 15, 2029 A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection Trial Milestone Phase 2/Phase 3
September 22, 2030 Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU) Trial Milestone Phase 4

Track MIRM alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open MIRM in the tracker

Recent history

DateEventTypePhase
October 13, 2026 8-K filed: Other event Filing —
September 28, 2026 8-K filed: Other event Filing —
September 8, 2026 8-K filed: Leadership change Corporate —
August 15, 2026 A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) Trial Milestone Phase 3
August 5, 2026 Quarterly results filed (8-K) Earnings —
July 8, 2026 A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379 Trial Milestone Phase 1
May 18, 2026 8-K filed: Material agreement, Other event Corporate —
May 6, 2026 Quarterly results filed (8-K) Earnings —
May 4, 2026 8-K filed: Other event Filing —
April 27, 2026 8-K filed: Other event Filing —
February 25, 2026 Quarterly results filed (8-K) Earnings —
February 20, 2026 A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) Trial Milestone Phase 2
January 26, 2026 8-K filed: Acquisition completed, Reg FD disclosure, Other event Corporate —
January 12, 2026 Quarterly results filed (8-K) Earnings —
December 19, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
December 19, 2025 8-K filed: Other event Filing —
December 8, 2025 8-K filed: Material agreement, Reg FD disclosure, Other event Corporate —
November 17, 2025 8-K filed: Other event Filing —
November 4, 2025 Quarterly results filed (8-K) Earnings —
August 6, 2025 Quarterly results filed (8-K) Earnings —
May 7, 2025 Quarterly results filed (8-K) Earnings —
April 23, 2025 An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) Trial Milestone Phase 3
December 17, 2024 A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). Trial Milestone Phase 2
September 4, 2024 MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study Trial Milestone Phase 2
November 7, 2023 Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai Trial Milestone Phase 2
July 13, 2023 Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) Trial Milestone Phase 3
December 7, 2022 A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA) Trial Milestone Phase 2
September 1, 2022 A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) Trial Milestone Phase 3
June 17, 2020 An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) Trial Milestone Phase 2
June 1, 2020 An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.